BCAL Diagnostics Ltd
BDX
Company Profile
Business description
BCAL Diagnostics Ltd is an Australian health care company engaged in early cancer detection. BCAL launched its first test, BREASTESTplus, as a rule-out test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTESTplus is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women. BCAL holds an exclusive license with ClearNote Health Inc., a U.S-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.
Contact
GPO Box Q128
Queen Victoria Building
SydneyNSW1230
AUSSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,882.00 | 35.10 | -0.39% |
| CAC 40 | 7,811.26 | 110.42 | -1.39% |
| DAX 40 | 25,371.75 | 273.29 | -1.07% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,725.03 | 27.85 | -0.26% |
| HKSE | 22,934.68 | 717.19 | -3.03% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,159.41 | 748.43 | -1.19% |
| NZX 50 Index | 13,709.78 | 37.06 | -0.27% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,768.30 | 24.90 | -0.28% |
| SSE Composite Index | 3,658.03 | 55.00 | -1.48% |